June 5, 2017
Odan Laboratories Ltd (Odan) and Sanofi-Aventis Canada Inc. (Sanofi Canada) have signed an agreement on May 8th, 2017 whereby Odan has licensed the rights from Sanofi Canada to commercialize two brands – Flagyl® capsules (an antibacterial/antiprotozoal) and Suprax® tablets and suspension (a broad-spectrum antibiotic).
Under this agreement, Odan will take over commercialization rights for these products in the Canadian marketplace and will be responsible for sales and supply to healthcare institutions, retailers, buyer groups, and other parties.
‘We are excited about this opportunity that is consistent with and fortifies Odan’s position as a leader in the speciality generic market’, commented Howard Kaminsky,President of Odan.’We are looking forward to other similar opportunities that are in the best interest of Canadian patients’.
Odan Laboratories is an independent, privately-owned pharmaceutical company founded in 1974 in Montréal, Québec, Canada. Through its fully integrated R&D and Manufacturing capabilities, as well as through key partnerships, Odan is growing strategically with a focus on specialty generic, niche, single-source, high-entry barrier products.
Tel: (514) 448-4901 #2293